Treatment
Dapagliflozin clinical trials
We’re tracking 92 recruiting studies that include Dapagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT07662109RecruitingPhase 3
Testing a new combo pill for type 2 diabetes
This study tests if a new medicine (elecoglipron) combined with dapagliflozin is safe and works better for adults with type 2 diabetes that isn't well controlled by diet or other medications.
Huntsville, AlabamaAges 18 years+ - NCT07662044RecruitingPhase 3
Studying elecoglipron for type 2 diabetes
This trial tests a new medicine called elecoglipron, taken alone or with another diabetes drug (dapagliflozin), to see if it helps control blood sugar better than a placebo. It may be an option if your current treatment isn't working well enough.
Birmingham, AlabamaAges 18 years+ - NCT06677060RecruitingPhase 3
Study of baxdrostat plus dapagliflozin for heart risk in type 2 diabetes
This study tests whether a new drug called baxdrostat, when added to the diabetes medicine dapagliflozin (Farxiga), can prevent heart failure and heart-related death in people with type 2 diabetes, high blood pressure, and existing heart or blood vessel disease. You may be able to join if you have type 2 diabetes, heart or blood vessel disease, high blood pressure, and at least one extra risk factor for heart failure.
Birmingham, AlabamaAges 40 years+ - NCT07482943RecruitingPhase 4
Dapagliflozin for heart function after Fontan procedure
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
Hong KongAges 12 years+ - NCT06307652RecruitingPhase 3
Testing a new heart failure and kidney treatment combo
This study tests a new combination of two medicines (balcinrenone and dapagliflozin) for people with heart failure and reduced kidney function. The goal is to see if this combination helps improve heart and kidney health better than current treatments.
Alexander City, AlabamaAges 18–130 - NCT06890143RecruitingPhase 3
Dapagliflozin for kids with genetic kidney disease and protein in urine
This trial tests if dapagliflozin, a medication that lowers blood sugar and protects the kidneys, can reduce protein in the urine of children with inherited kidney disease. It may help preserve kidney function when added to standard blood pressure medication.
Shanghai, Shanghai MunicipalityAges 6–18 - NCT07025629RecruitingPhase 3
Dapagliflozin after ICU discharge for heart and kidney health
This study tests if the drug dapagliflozin (a medicine that helps protect the heart and kidneys) can improve recovery in patients who needed a breathing machine or blood pressure support in the ICU. If you qualify, you would take the drug after leaving the ICU to see if it lowers the risk of heart or kidney problems.
ParisAges 18 years+ - NCT06420167RecruitingPhase 2
Dapagliflozin for kidney AL amyloidosis
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
Detroit, MichiganAges 18 years+ - NCT06783166RecruitingPhase 2/Phase 3
Comparing two medications for acute heart failure with fluid buildup
This trial tests if dapagliflozin or acetazolamide works better for people hospitalized with heart failure who have extra fluid in their body (congestion). The study will compare how well each medication helps remove fluid when used with standard IV diuretics.
Al MansurahAges 18 years+ - NCT06398977Recruiting
Dapagliflozin to protect kidney function in dialysis patients
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
Chengdu, SichuanAges 18–75 - NCT06762964RecruitingPhase 2
Dapagliflozin for Failing Fontan Circulation
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
Rochester, MinnesotaAges 18 years+ - NCT06845163RecruitingPhase 2
Testing dapagliflozin for diabetic macular edema
This study tests whether a medication called dapagliflozin, which is usually used for diabetes and heart failure, can help reduce swelling in the retina (diabetic macular edema) and improve vision. It is for people with type 2 diabetes who are already taking insulin and metformin.
Alexandria, Alexandria GovernorateAges 18–85 - NCT06535529RecruitingPhase 3
Comparing Two Water Pills for Worsening Heart Failure
This study compares two medicines—acetazolamide and dapagliflozin—to see which works better at removing extra fluid in people hospitalized for worsening heart failure. It may help decide the best treatment for fluid overload.
CairoAges 18 years+ - NCT07239011RecruitingPhase 1/Phase 2
Dapagliflozin for depression study
This trial tests whether dapagliflozin, a diabetes medication, can help treat major depression. It is for adults who have been depressed for at least 2 months and score high on a depression scale.
Damietta, New DamiettaAges 18–60 - NCT07684326RecruitingPhase 2/Phase 3
Can dapagliflozin help liver cirrhosis with fluid buildup? (Phase 2/3 randomized trial)
This trial tests a diabetes pill (dapagliflozin) to see if it helps people with liver cirrhosis and fluid buildup (ascites). The goal is to improve fluid balance and possibly reduce hospital stays.
GizaAges 18 years+ - NCT04707261RecruitingPhase 4
Testing how dapagliflozin affects anemia in heart failure
This trial studies whether dapagliflozin (a heart-failure medicine) can improve anemia in people with heart failure. It may help explain why some patients feel better and how anemia changes when this medicine is used.
Xiangtan, HunanAges 18–100 - NCT05174052RecruitingPhase 3
Dapagliflozin for heart rhythm problems in diabetes
This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.
Oklahoma City, OklahomaAges 18–85 - NCT05359263RecruitingPhase 2
Dapagliflozin for kidney disease to improve heart structure
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
CopenhagenAges 18 years+ - NCT05762952RecruitingPhase 1
Dapagliflozin study for heart micro-blood-flow symptoms in women
This early-phase study tests whether dapagliflozin can improve tiny blood-vessel function in women who have heart-ache-like symptoms but no major blockage on heart scans. If it works, it may help symptoms related to “microvascular” heart circulation problems.
Charlottesville, VirginiaAges 18–99 - NCT05764057RecruitingPhase 3
Dapagliflozin to help the heart heal after a heart attack
This trial tests whether dapagliflozin (a diabetes medicine also used for heart protection) can reduce harmful heart “remodeling” after an acute heart attack. It may help your heart function and structure recover over the following 6 months.
ParisAges 18 years+ - NCT05788276RecruitingPhase 4
Dapagliflozin to help transplanted kidneys stay healthy
This study tests whether dapagliflozin can preserve the structure and function of a kidney transplant. You may be asked to take dapagliflozin on top of usual transplant medicines to see if it helps the new kidney work better over time.
Oslo, OsloAges 18–75 - NCT05944016RecruitingPhase 3
Dapagliflozin for early Alport kidney disease in teens and young adults
This trial tests dapagliflozin, a daily medicine, to slow kidney problems in people with early-stage chronic kidney disease caused by Alport syndrome. It may help protect kidney function and reduce worsening over time.
Heidelberg, Baden-WürttenbergAges 10–39 - NCT05986136RecruitingPhase 2/Phase 3
Dapagliflozin for mild to moderate ulcerative colitis
This study tests whether dapagliflozin (a medicine often used for diabetes) can help calm inflammation in people with mild to moderate ulcerative colitis. It's a new way of treating UC by working with the body's natural cleanup process.
Al MansurahAges 1.5 years–60 years - NCT05989347RecruitingPhase 1
Dapagliflozin with chemo for breast cancer
This trial tests whether adding the drug dapagliflozin (a pill that lowers blood sugar) to standard chemotherapy before breast cancer surgery can improve outcomes. It is for women with high insulin levels and a higher BMI who are about to start chemotherapy.
New Haven, ConnecticutAges 18 years+
What Dapagliflozin is being studied for
Conditions with recruiting Dapagliflozin studies.
Common questions
- Are there clinical trials studying Dapagliflozin?
- Yes. Clin2 currently lists 92 recruiting studies that include Dapagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dapagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dapagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dapagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.